Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Rapid Dose Therapeutics Corp C.DOSE

Alternate Symbol(s):  RDTCF

Cannabis
Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. It provides disruptive drug delivery technologies designed to improve patient outcomes. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream... see more

CSE:DOSE - Post Discussion

Rapid Dose Therapeutics Corp > Monthly report
View:
Post by lscfa on Apr 11, 2023 1:46pm

Monthly report

The Company has received comments from the OSC in regards to its Application and responded to the comments by letter dated March 16, 2023. The OSC replied to our response letter with a second set of comments on March 28, 2023. The Company responded to this second of comments on April 3, 2023 and awaits further communication from the OSC in regards tothe status of the Application.
 


https://webfiles.thecse.com/CSE_Form_7_March_31_2023_Rapid_Dose_Therapeutics_Corp.docx?2hFpJm_WhhymooE2hkUub1aO5OQCEHHK

Be the first to comment on this post
Rapid Dose Therapeutics Corp